<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02766686</url>
  </required_header>
  <id_info>
    <org_study_id>STR - ProtoChoice-P - 2015</org_study_id>
    <nct_id>NCT02766686</nct_id>
  </id_info>
  <brief_title>Preference-based Comparative Study on Definitive Radiotherapy of Prostate Cancer With Protons</brief_title>
  <acronym>ProtoChoice-P</acronym>
  <official_title>Preference-based Comparative Study on Definitive Radiotherapy of Prostate Cancer With Protons in Standard Fractionation and Standard Dosage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Consortium for Translational Cancer Research (DKTK)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Radiation Research in Oncology Dresden/Heidelberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radiation Oncology Working Group of the German Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ProtoChoice-P is a prospective multicenter trial to evaluate proton therapy in patients
      suffering from prostate cancer. Primary aim of the study is a decrease of moderate or severe
      genito-urinary or intestinal side effects (Common Terminology Criteria for Adverse Events
      (CTCAE) 4.0 grade 2 or higher) by the use of proton therapy. Secondary endpoints contain
      assessment of quality of life, biochemical recurrence and recurrence free survival as well as
      overall survival and economic comparison between photon and proton therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hypothesis of the study is a 7.5% decrease of combined genito-urinary and intestinal side
      effects from 15% with photon therapy to 7.5% by the use of protons. With an alpha of 0.05 and
      80% power it is therefore necessary to treat 131 patients with protons to detect such
      difference. With an estimated drop-out rate of 10% 146 patients have to be recruited to the
      proton arm. As randomization to photon or proton therapy is not possible in a multicenter
      setting with only few proton facilities available patients treated with photons will be
      prospectively matched to their proton counterparts. Stratification criteria will include:
      Age, high dose volume, androgen deprivation, history of surgery, obstructive disease,
      increased risk for rectal bleeding, socio-economic criteria and use of rectal balloon during
      radiotherapy. Comparison of the primary endpoint will be restricted to patients without
      irradiation of lymphatic drainage.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative incidence of moderate/ severe side effects</measure>
    <time_frame>after 2 years ( measured from the first day of treatment)</time_frame>
    <description>≥ grade 2 by CTCAE combined for genito-urinary and gastrointestinal side effects</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">146</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Radiotherapy with protons</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Proton radiotherapy 74-80 Gray equivalent (GyE), 2Gy per fraction, 5 fractions peer week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiotherapy with photons</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Photon-Intensity-Modulated Radiation Therapy (IMRT) without lymph drainage vessels, 74-80 Gy, 2Gray (Gy) per fraction, 5 fractions peer week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiotherapy with photons with lymph drainage vessels</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Photon-IMRT with lymph drainage vessels, 74-80 Gy, 2Gy per fraction, 5 fractions peer week</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy with protons</intervention_name>
    <arm_group_label>Radiotherapy with protons</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy with photons</intervention_name>
    <arm_group_label>Radiotherapy with photons</arm_group_label>
    <arm_group_label>Radiotherapy with photons with lymph drainage vessels</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  life expectancy ≥ 10 years

          -  adenocarcinoma of the prostate confirmed by punch biopsy

          -  locally limited to locally advanced adenocarcinomas without evidence of distant
             metastases i.e. T1-3b N0-1 M0

          -  stage-related indicated neoadjuvant / adjuvant androgen deprivation possible
             (neoadjuvant ≤ 6 months)

          -  good general condition (ECOG performance status 0 - 1)

          -  marker seed implantation before irradiation (optional) or possibility of Image-guided
             Radiation Therapy (IGRT) by CT

          -  adequate compliance for follow-up

          -  written informed consent

        Exclusion Criteria:

          -  distant metastases

          -  previous radiotherapy of the lesser pelvis

          -  previous or concomitant other malignant disease except when there is no impact on
             treatment or follow-up of the prostate cancer

          -  participation in another clinical study, if it's excluded by the study protocols
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tobias Hölscher, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Technology, University Hospital Carl Gustav Carus, Department of Radiation Therapy and Radiation Oncology, German Consortium for Translational Cancer Research (DKTK)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tobias Hölscher, Dr.</last_name>
    <phone>+49 351 458 2238</phone>
    <email>str.studien@uniklinikum-dresden.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hölscher Tobias, Dr.</last_name>
    <phone>+49 351 458 2238</phone>
    <email>str.studien@uniklinikum-dresden.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Carl Gustav Carus, Department of Radiotherapy and Radiation Oncology</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Baumann, Prof.</last_name>
      <phone>+49 351 458 2238</phone>
      <email>str.studien@uniklinikum-dresden.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar, Technische Universität München</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephanie Combs, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Radioonkologie, Universitätsklinikum Tübingen</name>
      <address>
        <city>Tubingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zips Daniel, Prof.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2016</study_first_submitted>
  <study_first_submitted_qc>May 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2016</study_first_posted>
  <last_update_submitted>November 3, 2017</last_update_submitted>
  <last_update_submitted_qc>November 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Technische Universität Dresden</investigator_affiliation>
    <investigator_full_name>Tobias Hölscher</investigator_full_name>
    <investigator_title>Dr. Tobias Hölscher</investigator_title>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <keyword>proton radiotherapy</keyword>
  <keyword>photon radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

